نتائج البحث 51-60 من 18708 لعملية البحث عن LL-37
Hu, M.D.. التصفّح Doctor search. السابقالصفحة السابقة · توجّه للصفحة 11 · توجّه للصفحة 22 ... 37 Replies Wed, Jul 15, 2026. darshsingh1. Can a hodgkins lymphoma ...
... II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and ...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer ...
... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...
... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...
Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...
The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events at 2 years of follow up ...
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.